Posted by admin on Jul 28th, 2022

Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.95 and traded as low as $3.56. Harvard Bioscience shares last traded at $3.69, with a volume of 58,695 shares changing hands.

Several equities analysts have recently weighed in on HBIO shares. TheStreet downgraded Harvard Bioscience from a “c” rating to a “d+” rating in a report on Monday, May 23rd. StockNews.com began coverage on Harvard Bioscience in a report on Thursday, March 31st. They set a “hold” rating for the company.

The company has a debt-to-equity ratio of 0.61, a current ratio of 2.18 and a quick ratio of 1.13. The company has a market capitalization of $152.18 million, a PE ratio of -23.06 and a beta of 1.78. The firm has a 50-day moving average of $3.71 and a 200 day moving average of $4.95.

Harvard Bioscience (NASDAQ:HBIO – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The medical instruments supplier reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). Harvard Bioscience had a negative net margin of 5.38% and a positive return on equity of 9.06%. The business had revenue of $28.78 million for the quarter, compared to analysts’ expectations of $29.10 million. During the same period last year, the business earned $0.03 earnings per share. As a group, research analysts anticipate that Harvard Bioscience, Inc. will post 0.26 earnings per share for the current fiscal year.

In other Harvard Bioscience news, CEO James W. Green acquired 30,000 shares of the company’s stock in a transaction that occurred on Friday, May 6th. The shares were bought at an average cost of $3.78 per share, with a total value of $113,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,309,955 shares of the company’s stock, valued at approximately $8,731,629.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO James W. Green acquired 10,000 shares of Harvard Bioscience stock in a transaction on Monday, May 9th. The shares were acquired at an average price of $3.40 per share, with a total value of $34,000.00. Following the purchase, the chief executive officer now directly owns 2,319,955 shares in the company, valued at approximately $7,887,847. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO James W. Green bought 30,000 shares of the business’s stock in a transaction dated Friday, May 6th. The shares were bought at an average cost of $3.78 per share, for a total transaction of $113,400.00. Following the transaction, the chief executive officer now owns 2,309,955 shares in the company, valued at approximately $8,731,629.90. The disclosure for this purchase can be found here. 6.20% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of HBIO. Essex Investment Management Co. LLC raised its position in shares of Harvard Bioscience by 8.2% in the 4th quarter. Essex Investment Management Co. LLC now owns 411,875 shares of the medical instruments supplier’s stock worth $2,904,000 after acquiring an additional 31,139 shares in the last quarter. B. Riley Asset Management LLC acquired a new position in shares of Harvard Bioscience in the fourth quarter valued at about $4,275,000. Bailard Inc. acquired a new position in shares of Harvard Bioscience in the fourth quarter valued at about $104,000. Raymond James & Associates purchased a new stake in shares of Harvard Bioscience in the fourth quarter worth about $240,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Harvard Bioscience in the fourth quarter worth about $101,000. Hedge funds and other institutional investors own 72.75% of the company’s stock.

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Wayside Technology Group (NASDAQ:WSTG) Stock Passes Below 200 Day Moving Average of $33.02

Graphite One (CVE:GPH) Share Price Passes Below Two Hundred Day Moving Average of $1.59